--- title: "AI \"Calculates\" New Drugs! China's Pharmaceutical Valley Enterprise Biocytogen Launches New-Generation Intelligent R&D Platform" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/41576547.md" description: "According to the Daxing District Media Convergence Center, recently, at the "BioX Innovation Forum", the company Biocytogen, which is rooted in the Daxing Biomedical Industry Base, officially launched the new generation AI-driven antibody discovery platform—RenSuper Workstation. This marks the official launch of an intelligent platform that can make new drug R&D as efficient as "precise retrieval in a database", adding another heavyweight tool to Daxing District's "AI + Healthcare" industry cluster. Simplifying Complexity: AI Makes Finding "Life-saving Drugs" as Easy as "Full-Web Search" In the past..." datetime: "2026-06-08T02:33:20.000Z" locales: - [en](https://longbridge.com/en/topics/41576547.md) - [zh-CN](https://longbridge.com/zh-CN/topics/41576547.md) - [zh-HK](https://longbridge.com/zh-HK/topics/41576547.md) author: "[若波投研](https://longbridge.com/en/profiles/26711817.md)" --- # AI "Calculates" New Drugs! China's Pharmaceutical Valley Enterprise Biocytogen Launches New-Generation Intelligent R&D Platform **Daxing District Media Center News** Recently, at the "BioX Innovation Forum", **Biocytogen, a company rooted in the Daxing Biomedical Industry Base, officially launched a new generation AI-driven antibody discovery platform—RenSuper Workstation,** marking the official launch of an intelligent platform that can make new drug R&D as efficient as "precise retrieval in a database". This adds another heavyweight tool to Daxing District's "AI + Healthcare" industry cluster.   **Simplifying Complexity** **AI Makes Finding "Life-Saving Drugs" as Easy as "Searching the Web"** In the past, developing a new antibody drug often required a long and uncertain "mass screening" process. **The newly launched RenSuper Workstation is like equipping new drug R&D with a super-intelligent "search engine" and "fully automated factory".** This platform integrates a real fully human antibody library, NGS, AI high-throughput screening, and automated intelligent manufacturing capabilities, building a closed-loop discovery and development platform from target to lead molecule.   ![Image](https://pub.pbkrs.com/uploads/2026/a9aa149a92607b794df3208b1761bd54?x-oss-process=style/lg) **In terms of AI screening capabilities, RenSuper has already obtained data validation on multiple high-difficulty, clinically validated targets.** Taking the RenNano fully human heavy-chain-only antibody platform as an example, the average positive hit rate based on SPR affinity evaluation reached 46%, with a maximum of 98%; under the AI+NGS-driven quality control system, the success rate for high-purity (≥90%) expression of FC format antibodies in 2026 reached 82%, further validating the platform's significant advantages in candidate molecule developability and conversion efficiency.  At the same time, the platform's "High-Throughput Antibody Intelligent Manufacturing Center" has achieved fully automated operation throughout the entire process. Relying on the automated intelligent manufacturing system, antibody protein output capacity is stable at an average of 50–100 mg, capable of processing 800 samples per day and up to 5000 samples per week, significantly improving the efficiency, stability, and certainty of antibody discovery and development. ![Image](https://pub.pbkrs.com/uploads/2026/ddf4fb747bc9117353d2abcec854a6d9?x-oss-process=style/lg) Dr. Shen Yuelei, Chairman and CEO of Biocytogen, stated: "Future new drug discovery will definitely be led by efficient, data-driven intelligent capabilities. **RenSuper's goal is to make antibody discovery searchable, scalable, and more efficient, allowing new drugs to benefit patients faster.**"   **Gathering Chains to Form Clusters** **China's Medicine Valley Takes the Lead in the New "AI+Biopharma" Track** The major upgrade of Biocytogen's intelligent platform is a vivid reflection of Daxing District's active response to Beijing's "Action Plan to Accelerate the Innovative Development of 'Artificial Intelligence + Healthcare' (2025-2027)".   ![Image](https://pub.pbkrs.com/uploads/2026/17c7f53bb9c1179b840c277a363c5af7?x-oss-process=style/lg) In recent years, relying on municipal policy guidance, **the Daxing Biomedical Industry Base has continued to focus on industrial transformation and upgrading, actively supporting park enterprises to iterate towards digitalization and intelligence.** Today's China's Medicine Valley not only has Biocytogen's new generation AI-driven antibody discovery platform—RenSuper Workstation, but also gathers benchmark platforms such as Jitai Technology's world-first AI nano-delivery platform NanoForge and Rejing Bio's X-Gen AI New Drug Discovery and Design Research Center. The clustered innovation trend of "AI+Pharmaceuticals" has already taken shape. In the future, the Daxing Biomedical Industry Base will continue to deeply cultivate new scenarios and tracks of "Artificial Intelligence + Biological Data", deepen the collaborative innovation of the entire industry-academia-research-medical application chain, and fully promote the high-quality development of the capital's healthcare industry. Source: This is Daxing $BIOCYTOGEN-B(02315.HK) $Biocytogen(688796.SH) ### Related Stocks - [688796.CN](https://longbridge.com/en/quote/688796.CN.md) - [02315.HK](https://longbridge.com/en/quote/02315.HK.md) - [07666.HK](https://longbridge.com/en/quote/07666.HK.md) - [688068.CN](https://longbridge.com/en/quote/688068.CN.md)